Bladder Adenocarcinoma: A Case Report

Sabbar Shukri Al-Bayaty; Ali Amer Abbas; Mohammed Abdulridha Mahdi Al-saffar; Shahbaa Ahmed Al-Qadasi; Mustafa Hafudh Hammoodi; Sarmad Qahtan Al-Salihi

doi:10.55544/jrasb.2.6.29

Authors

Sabbar Shukri Al-Bayaty Baghdad Medical City, Al-Amal Oncology Hospital, IRAQ.
Ali Amer Abbas Baghdad Medical City, Al-Amal Oncology Hospital, IRAQ.
Mohammed Abdulridha Mahdi Al-saffar Al-Saheed Al-sader Hospital, Baghdad, IRAQ.
Shahbaa Ahmed Al-Qadasi Baghdad Medical City, Al-Amal Oncology Hospital, IRAQ.
Mustafa Hafudh Hammoodi Baghdad Medical City, Al-Amal Oncology Hospital, IRAQ.
Sarmad Qahtan Al-Salihi Baghdad Medical City, Al-Amal Oncology Hospital, IRAQ.

DOI:

https://doi.org/10.55544/jrasb.2.6.29

Keywords:

Urinary Bladder Neoplasms, Adenocarcinoma, Surgical Pathology

Abstract

Background: Bladder adenocarcinoma (AC) is a rare histological variant and research on the best ways to treat it is scant.

Clinical Case: We present the case of a 70-year-old woman who has had hematuria for the past month with no history of serious illness. She visited a urologist, who performed a cystoscopy on her as a result. A urinary bladder adenocarcinoma was discovered in a biopsy. Complete investigations revealed no metastasis. The patient was considered for a partial cystectomy, according to the results of the MRI. She underwent the surgery, which was followed by concurrent chemo-radiotherapy. She underwent multiple reevaluations, and her case was stable after about a year of follow-up.

Conclusions: With the best surgical outcomes, the choice to perform a partial cystectomy was appropriate given the tumor's location. However, a lengthy follow-up is required.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Black PC, Brown GA, Dinney CP. The impact of variant histology on the outcome of bladder cancer treated with curative intent. Urol Oncol. 2009; 27:3-7.

Otero JR, Ojeda JMD, Betriu GC, et al.: Adenocarcinoma vesical primario: nuestra experiencia. Actas Urol Españolas. 2005; 29(3):257-260.

Tejeda-Mariaca JE, Ordoñez-Alcantara M, Bello-Sedano A, Perez-Cornejo V, Grandez-Urbina JA. Case Report: Bladder adenocarcinoma: primary or urachal? F1000Res. 2019; 8:1717.

Dadhania V, Czerniak B, Guo CC: Adenocarcinoma of the urinary bladder. Am J Clin Exp Urol. 2015; 3(2):51-63.

Vijayakumar V, Natesan G, Sudhakar M, Prakasam U, Seeralan V, Kaliyaperumal M, et al. Primary Mucinous Adenocarcinoma of the Bladder: Case Report and Review of Literature. Indian J Surg Oncol. 2020;11(Suppl 1):44–7.

Baffigo G, Delicato G, Bianchi D, Signore S, Tartaglia E, Corvese F, Perla A, Marino B, Santeusanio G, Ferdinandi V. Mucinous adenocarcinoma of the urinary bladder. Am J Case Rep. 2012; 13:99-101.

Pan X, Jin L, He T, Hu J, Quan J, Zhou L, Ni L, Yang S, Mao X, Lai Y. Mucinous adenocarcinoma of the bladder: A case report and review of the literature. Mol Clin Oncol. 2016; 5(4):447-448.

Szarvas T, Módos O, Niedworok C, et al.: Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases. Urol Oncol. 2016; 34(9):388-398.

Flaig TW, Spiess PE, Agarwal N, et al.: NCCN Guidelines Insights: Bladder Cancer, Version 5. 2018. J Natl Compr Canc Netw. 2018; 16(9):1041-1053.